These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9120223)

  • 1. 3,4-diaminopyridine in childhood myasthenia: double-blind, placebo-controlled trial.
    Anlar B; Varli K; Ozdirim E; Ertan M
    J Child Neurol; 1996 Nov; 11(6):458-61. PubMed ID: 9120223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
    Sanders DB; Howard JF; Massey JM
    Ann N Y Acad Sci; 1993 Jun; 681():588-90. PubMed ID: 8357206
    [No Abstract]   [Full Text] [Related]  

  • 3. 3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies.
    Evoli A; Alboini PE; Damato V; Iorio R
    Neurology; 2016 Mar; 86(11):1070-1. PubMed ID: 26873957
    [No Abstract]   [Full Text] [Related]  

  • 4. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
    Oh SJ; Claussen GG; Hatanaka Y; Morgan MB
    Muscle Nerve; 2009 Nov; 40(5):795-800. PubMed ID: 19722254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of experimental autoimmune myasthenia gravis in rabbits with 4-aminopyridine and 3,4-diaminopyridine].
    Li L; Zhang YP
    Zhongguo Yao Li Xue Bao; 1994 Jul; 15(4):358-62. PubMed ID: 7801782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.
    Palace J; Wiles CM; Newsom-Davis J
    J Neurol Neurosurg Psychiatry; 1991 Dec; 54(12):1069-72. PubMed ID: 1783919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
    Lundh H; Nilsson O; Rosén I
    Eur Arch Psychiatry Neurol Sci; 1985; 234(6):374-7. PubMed ID: 2992990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.
    Howard JF; Barohn RJ; Cutter GR; Freimer M; Juel VC; Mozaffar T; Mellion ML; Benatar MG; Farrugia ME; Wang JJ; Malhotra SS; Kissel JT;
    Muscle Nerve; 2013 Jul; 48(1):76-84. PubMed ID: 23512355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human type A botulism and treatment with 3,4-diaminopyridine.
    Davis LE; Johnson JK; Bicknell JM; Levy H; McEvoy KM
    Electromyogr Clin Neurophysiol; 1992; 32(7-8):379-83. PubMed ID: 1526219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
    Sanders DB; Massey JM; Sanders LL; Edwards LJ
    Neurology; 2000 Feb; 54(3):603-7. PubMed ID: 10680790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects].
    Vílchez JJ; Casanova B; Monte E
    Med Clin (Barc); 1996 Jan; 106(1):37-8. PubMed ID: 8750543
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
    Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
    Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis and therapy of congenital myasthenia syndrome].
    Sieb JP
    Dtsch Med Wochenschr; 1999 Jan; 124(1-2):24-9. PubMed ID: 9951456
    [No Abstract]   [Full Text] [Related]  

  • 14. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study.
    Meriggioli MN; Rowin J; Richman JG; Leurgans S
    Ann N Y Acad Sci; 2003 Sep; 998():494-9. PubMed ID: 14592919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
    Polman CH; Bertelsmann FW; de Waal R; van Diemen HA; Uitdehaag BM; van Loenen AC; Koetsier JC
    Arch Neurol; 1994 Nov; 51(11):1136-9. PubMed ID: 7980110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.
    Lundh H; Nilsson O; Rosén I
    Neurology; 1984 Oct; 34(10):1324-30. PubMed ID: 6541305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
    Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
    J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.
    Gajdos P; Tranchant C; Clair B; Bolgert F; Eymard B; Stojkovic T; Attarian S; Chevret S;
    Arch Neurol; 2005 Nov; 62(11):1689-93. PubMed ID: 16286541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
    Lorenz D; Hagen K; Ufer M; Cascorbi I; Deuschl G; Volkmann J
    Neurology; 2006 Jun; 66(11):1753-5. PubMed ID: 16769957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials.
    Vrinten C; Lipka AF; van Zwet EW; Schimmel KJ; Cornel MC; Kuijpers MR; Hekster YA; Weinreich SS; Verschuuren JJ
    BMJ Open; 2015 Jul; 5(7):e007863. PubMed ID: 26185179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.